Summary
The current prospective randomized study was designed to compare the effects of intracavitary (i.c.) chemotherapy vs immunotherapy vs immunochemotherapy for malignant effusion. Between 1992 and 1995, a total of 42 patients with malignant effusion were registered, and 41 patients were eligible for statistical analysis. The primary diseases of the eligible patients included 27 gastric, four colorectal, four pancreatic, three lung, two liver and one oesophageal cancers. The patients with malignant effusion were randomly assigned into one of three i.c. therapeutic regimens: chemotherapy alone with weekly injection of anticancer agents (ACAs: cisplatin, mitomycin-C, adriamycin, etc.) (Group A, n = 13); immunotherapy alone with weekly injection of streptococcal preparation OK-432 (Group B, n = 14); or immunochemotherapy with ACAs and OK-432 (Group C, n = 14). The response of the effusion, patient survival and the kinetics of cytokines in the effusion were compared. There were no differences in the patients’ backgrounds. The side-effects of the regimens included pain, anorexia, fever, leucopenia and anaemia and there were no differences in their incidence among the three groups. One patient died after cisplatin (CDDP) administration in Group A. Cytologic examination revealed that tumour cells in the effusion disappeared in 23% of Group A cases, 36% of Group B cases and 36% of Group C cases. The malignant effusion did not disappear in any of the Group A cases; however, the effusion disappeared in 29% of Group B cases and 43% of Group C cases (P = 0.03, Group A vs Group C). Furthermore, the 50% survival period was 1.6 months for Group A, 2.4 months for Group B and 3.5 months for Group C. The 6-month survival rate was 7% for Group A, 6% for Group B and 34% for Group C, and the 1-year survival rate was 0%, 0% and 17% respectively (P = 0.048, Group A vs Group C by the log-rank test). The analysis of the cytokine kinetics revealed a prominent increase in the level of interleukin-6 in the effusion in Group C. These results suggest that i.c. immunochemotherapy with OK-432 and ACAs may be more beneficial than i.c. chemotherapy alone or immunotherapy alone.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allavena, P., Pirovano, P., Bonazzi, C., Colombo, N., Mantovani, A. & D’Incalci, M. (1990). In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst 82: 139–142.
Bier, H. (1987). Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy; II. Chemotherapy and T lymphocyte depression. J Otorhinolaryngeal Relat Spec 49: 57–66.
Bier, H. & Bier, J. (1987). Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy; I. Chemotherapy and tumor-specific immunity. J Otorhinolaryngeal Relat Spec 49: 48–55.
Ehrke, M. J., Ryoyama, K. & Cohen, S. A. (1984). Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 44: 2497–2504.
Fujita, K. (1987). The role of adjunctive immunotherapy in superficial bladder cancer. Cancer 59: 2027–2030.
Fukuma, K., Matsuura, K., Shibata, S., Nakahara, K., Fujisaki, S. & Maeyama, M. (1986). Pseudomyoma peritonei: effect of chronic continuous immunotherapy with a streptococcal preparation, OK-432 after surgery. Acta Obstet Gynecol Scand 65: 133–137.
Gehan, E. A. (1965). A generalized Wilcoxon test for comparing arbitrarily singly-censored sample. Biometrika 52: 203–223.
Gehan, E. A. (1975). Statistical methods for survival time studies. In Cancer Therapy Prognostic Factors and Criteria of Response. A monograph of the European Organization for Research on Treatment of Cancer. Staquet MJ (ed), pp. 7–35. Raven Press: New York
George, S. L. & Desu, M. M. (1974). Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 27: 15–24.
Goto, M., Mitsuoka, A., Sugiyama, M. & Kitano, M. (1981). Enhancement of delayed hypersensitivity reaction with variety of anti-cancer drugs. J Exp Med 154: 204–209.
Heppner, G. H. & Calabresi, P. (1972). Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors. J Natl Cancer Inst 48: 1161–1167.
Inoue, K., Kan, N., Okino, T., Mise, K., Moriguchi, Y., Nio, Y. & Tobe, T. (1993). Surgical management of advanced gastric cancer with peritoneal involvement. Asian J Surg 16: 53–59.
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Katano, M. & Torisu, M. (1982). Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50: 62–68.
Kawagoe, K. & Masuda, H. (1986). Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432. Jpn J Clin Oncol 6: 137–142.
Kim, J. P. (1987). The concept of immunochemosurgery in gastric cancer. World J Surg 11: 465–472.
Kimura, I., Ohnishi, T., Yasuhara, S., Sugiyama, M., Urabe, Y., Fujii, M. & Machida, K. (1976). Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 37: 2201–2203.
Kitsuki, H., Uchiyama, A., Yoshida, T. & Torisu, M. (1994). OK-432-induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. Clin Immunol Immunopathol 71: 89–95.
Kleinerman, E. S., Zwelling, L. A., Schwartz, R. & Muchmore, A. V. (1980). Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet 22: 1102–1105.
Kyoto Research Group for Digestive Organ Surgery (1992). A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Ann Surg 216: 44–54.
Luh, K. T., Yang, P. C., Kuo, S. H., Chang, D. B., Yu, C. J. & Lee, L. N. (1992). Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. Cancer 69: 674–679.
Maehara, Y., Sugimachi, K., Akagi, M., Kakegawa, T., Shimazu, H. & Tomita, M. (1992). Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 65: 413–416.
Mantovani, A., Luini, W., Peri, G., Vecchi, A. & Spreafico, F. (1978). Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 61: 1255–1261.
Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Mizutani, Y., Nio, Y. & Yoshida, O. (1992a). The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes. Cancer 69: 2999–3007.
Mizutani, Y., Nio, Y. & Yoshida, O. (1992b). Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. J Urol 147: 505–510.
Mukai, M., Kubota, S., Morita, S. & Akanuma, A. (1995). A pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Cancer 75: 2276–2280.
Nio, Y., Ohgaki, K. & Tobe, T. (1989a). Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma. J Clin Lab Immunol 29: 37–43.
Nio, Y., Zighelboim, J., Berek, J. S. & Bonavida, B. (1989b). Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer 64: 434–441.
Nio, Y., Zighelboim, J., Berek, J. S. & Bonavida, B. (1990). Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nat Immun Cell Growth Regul 9: 283–296.
Ogita, S., Tsuto, T., Tokiwa, K. & Takahashi, T. (1987). Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg 74: 690–691.
Ono, T., Kurata, S., Wakabayashi, K., Sugawara, Y., Saito, M. & Ogawa, H. (1973). Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. GANN. Jpn J Cancer Res 64: 59–69.
Osterowski, M. (1986). An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 57: 721–727.
Paladine, W., Cunningham, T. J., Sponzo, R., Donovan, M., Olson, K. & Horton, J. (1976). Intracavitary bleomycin in the management of malignant effusions. Cancer 38: 1903–1908.
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J. & Smith, P. G. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39.
Rusch, V., Figlin, R., Godwin, D. & Piantadosi, S. (1991). Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9: 313–319.
Saito, M., Ichimura, O., Kataoka, M., Moriya, Y., Ueno, K., Sugawara, Y. & Nanjo, M. (1986). Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation. Cancer Immunol Immunother 22: 161–168.
Sakurai, Y., Tsukagoshi, S., Satoh, H., Akiba, T., Suzuki, S. & Takagaki, Y. (1972). Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep 56: 9–17.
Tokai Cooperative Study Group for Adjuvant Chemo-immunotherapy of Stomach Cancer (1981). A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 7: 5–10.
Torisu, M., Katano, M., Kimura, Y., Itoh, H. & Takesue, M. (1983). New approach to management of ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357–364.
Uchida, A. & Hoshino, T. (1980). Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45: 476–483.
Uchida, A. & Micksche, M. (1983). Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst 71: 673–680.
Ujiie, T. (1989). Increased sensitivity of tumor cells to immune defense cells following treatment with antineoplastic agents in vitro. Jpn J Exp Med 59: 17–26.
Watanabe, Y. & Iwa, T. (1987). Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Res Mod 6: 169–180.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nio, Y., Nagami, H., Tamura, K. et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80, 775–785 (1999). https://doi.org/10.1038/sj.bjc.6690421
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690421